Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study

被引：0
|
作者：
Taylor, P. [1 ]
Genovese, M. [2 ]
Keystone, E. [3 ]
Schlichting, D. [4 ]
Beattie, S. [5 ]
Macias, W. [4 ]
Lundmark, J. [6 ]
机构：
[1] Univ Oxford, Kennedy Inst Rheumatol, Oxford OX1 2JD, England
[2] Stanford Univ, Immunol & Rheumatol Clin, Stanford, CA 94305 USA
[3] Mt Sinai Hosp, Rebecca MacDonald Ctr Arthrit & Autoimmune Dis, Toronto, ON M5G 1X5, Canada
[4] Eli Lilly & Co, Corp Ct, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Global Stat Sci Autoimmune Platform, Indianapolis, IN USA
[6] Eli Lilly Sweden AB, Biomed, Solna, Sweden
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2014年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP201
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [21] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
  • [22] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
    Cohen, Stanley
    Pablos, Jose L.
    Pavelka, Karel
    Mueller, Gerard Anton
    Matsumoto, Alan
    Kivitz, Alan
    Wang, Hui
    Krishnan, Eswar
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [23] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
    Stanley Cohen
    Jose L. Pablos
    Karel Pavelka
    Gerard Anton Müller
    Alan Matsumoto
    Alan Kivitz
    Hui Wang
    Eswar Krishnan
    Arthritis Research & Therapy, 21
  • [24] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND CLINICAL AND RADIOGRAPHIC EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 7 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Terry, K. K.
    Kwok, K.
    Lazariciu, I.
    Nduaka, C.
    Connell, C. A.
    DeMasi, R.
    Wang, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 252 - 252
  • [25] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Studies up to 36 Months.
    Wollenhaupt, J.
    Silverfield, J. C.
    Lee, E. B.
    Wood, S.
    Soma, K.
    Wang, L.
    Nakamura, H.
    Komuro, Y.
    Nduaka, C. I.
    Gruben, D.
    Zwillich, S. H.
    Bradley, J. D.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S152 - S153
  • [26] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK-1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN OPEN-LABEL EXTENSION STUDY
    Genovese, Mark C.
    Kremer, Joel
    Zhong, Sheng
    Friedman, Alan
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S85 - S85
  • [27] Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
    Keystone, Edward C.
    Genovese, Mark C.
    Schlichting, Douglas E.
    de la Torre, Inmaculada
    Beattie, Scott D.
    Rooney, Terence P.
    Taylor, Peter C.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (01) : 14 - 21
  • [28] Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis: Interim data from OPAL Balance, an open label, long-term extension study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan J.
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Kudlacz, Elizabeth
    Menon, Sujatha
    Kanik, Keith S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB224 - AB224
  • [29] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 24 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: INTERIM DATA FROM OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, J. A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Hendrikx, T.
    Kanik, K. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 682 - 682
  • [30] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: LONG-TERM EXTENSION STUDY OUTCOMES IN AN AUSTRALIAN RHEUMATOID ARTHRITIS POPULATION
    Hall, S.
    Nash, P.
    Rischmueller, M.
    Bossingham, D.
    Cook, N.
    Witcombe, D.
    Kwok, K.
    Thirunavukkarasu, K.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 26 - 26
12345